ClinicalTrials.gg
WithdrawnNCT04983446Updated Oct 19, 2022

In-patient COVID-19 Study of Intranasal Foralumab

A Phase 2 interventional study of Foralumab and Placebo in Covid19, COVID-19 Lower Respiratory Infection and COVID-19 Respiratory Infection, sponsored by Tiziana Life Sciences LTD. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-19.

Sponsored by Tiziana Life Sciences LTD · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Withdrawn due to business reasons

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 2, randomized, placebo-controlled, double-blind, proof-of-concept study of intranasal foralumab in hospitalized subjects with severe COVID-19 and pulmonary inflammation.

Foralumab is a fully human second generation anti-CD3 mAb with a modified Fc unit (two amino acid substitutions) composed of 2 heavy chains with an immunoglobulin (Ig) G1constant region and 2 light chains with a kappa constant region.

In a separate Phase 2 randomized, controlled, pilot trial conducted to assess safety, tolerability, and efficacy in 39 patients with mild to moderate COVID-19 in Brazil, showed that intranasal foralumab may be of benefit in modulating immune reactivity and in reducing pulmonary inflammation. Importantly, intranasal administration of foralumab was well tolerated with no clinically significant changes in blood cell counts (including blood lymphocytes), no evidence of hypersensitivity, and no serious adverse events (SAEs) were reported in the study.

Read the detailed description

Approximately 80 hospitalized subjects with severe COVID-19 and evidence of pulmonary involvement on a computed tomography (CT) scan at screening will be enrolled in this study over 4 months, depending on enrollment. Up to 7 centers in Brazil will conduct this study.

The main study objective is to evaluate the effect of intranasal foralumab on evolution of pulmonary infiltrates in hospitalized subjects with severe COVID-19 pneumonia.

Subjects will be randomized 1:1 to receive intranasal foralumab 100 µg (50 µg in 0.1 ml solution into each nostril) or placebo (0.1 ml vehicle solution into each nostril). All subjects will receive continued Standard of Care (SoC) therapy (per hospital/study site policies and guidelines) together with intranasal foralumab or placebo for the entire 14-day treatment period.

Subjects will participate in the study approximately 35 days (from screening to completion).

02

Conditions studied

  • Covid19
  • COVID-19 Lower Respiratory Infection
  • COVID-19 Respiratory Infection

Browse trials for

03

In context

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Lead sponsor

Tiziana Life Sciences LTD is the lead sponsor of 14 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females ≥ 18 years of age hospitalized with severe COVID-19, who are within 2 weeks of symptom onset.
  2. Laboratory-confirmed SARS-CoV-2 infection as determined by nucleic acid amplification test (NAAT) from an upper respiratory specimen within 72 hours of randomization. Test type and result must be documented in the study record.
  3. Subject agrees to the collection and processing of blood and saliva samples, non-invasive oxygen monitoring (via pulse oximeter), nasal speculum examination, and radiography (high-resolution CT scanning) as required in the protocol.
  4. Subject (or their legally authorized representative [LAR]) is willing and able to provide written .
  5. Has at least 2 of the following symptoms for ≥ 48 hours: fever or history of fever (oral temp ≥ 38°C), cough, headache, fatigue, muscle aches, gastrointestinal symptoms, and/or shortness of breath.
  6. Respiratory rate ≥ 30 per minute, SpO2 ≤ 93% on room air at sea level, heart rate ≥ 125/min, and/or PaO2/FiO2 \< 300.
  7. Radiologic evidence of pneumonia (infiltrates on high-resolution CT) at screening.
  8. Erythrocyte sedimentation rate (ESR), CRP and/or lactate dehydrogenase (LDH) > [ULN] at screening.

Exclusion criteria

Exclusion Criteria:

  1. Age \< 18 years.
  2. Subject has a >35 kg/m2 or glycosylated (Hgb A1c) ≥ 9% at screening.
  3. Currently requires (or in opinion of Investigator is likely to require within 48 hours of enrollment) mechanical ventilation or extracorporeal membrane oxygen saturation (ECMO).
  4. Prior history (or considered to be at risk) of acute liver disease or chronic unstable liver disease ( B or C) OR (ALT) or aspartate transaminase (AST) > 5 × at screening.
  5. Prior history of requiring supplemental oxygen, or active/incompletely treated tuberculosis.
  6. Concomitant uncontrolled systemic bacterial or fungal infection OR concomitant viral infection other than COVID-19 (e.g., Influenza, respiratory syncytial virus).
  7. Any underlying condition or therapy associated with .
  8. Serious concomitant illness which in the opinion of the Investigator precludes the subject from enrolling in the trial.
  9. History of untreated syphilis, , or untreated virus.
  10. Uncontrolled .
  11. Acute kidney injury Stage 3 or higher or chronic kidney disease Stage 4 or higher.
  12. Known to foralumab or .
  13. Females of , who are pregnant, breast-feeding, intend to become pregnant or are not using highly effective methods. Females who are (defined as at least 12 months of amenorrhea) are not considered to be of child-bearing potential. Highly effective contraceptive methods are defined as:

    1. Having a male partner who is sterile (vasectomized or orchiectomized) prior to the female subject's entry into the trial and is the sole sexual partner for that female subject
    2. Surgically sterile (hysterectomy or bilateral oophorectomy); bilateral tubal ligation with surgery at least 6 weeks before study initiation
    3. Use of intra-uterine devices in place for at least 3 months
    4. Stable hormonal contraception for at least 3 months before study initiation and through study completion
    5. Barrier method (condom or diaphragm) with spermicide for at least 14 days before study initiation through study completion
    6. True abstinence: When this is in line with the preferred and usual lifestyle of the subject (period abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
  14. Active participation in any other clinical trial or receipt of an experimental treatment within the preceding 30 days.
  15. Receipt of COVID-19 convalescent plasma, or COVID-19 mAbs, within 3 months of enrollment.
  16. Receipt of any anti-IL-6 mAb or similar anti-inflammatory medications (e.g, Janus kinase inhibitors) within 3 months of enrollment.
  17. Prior receipt of any COVID-19 vaccine.
  18. Receipt of any treatment for COVID-19 (off-label, compassionate use, or use) except per local SoC within 30 days prior to screening.
  19. History of opioid or cocaine (including crack cocaine) use.
  20. Use of any nasally administered medications within 1 week of enrollment.
  21. In the opinion of the Investigator, the subject is unable to comply with the requirements to participate in the study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Foralumab Arm + Standard of Care

    Subjects in this arm would receive, intranasal foralumab 100 µg (50 µg in 0.1 ml solution into each nostril).

    Drug: Foralumab

  • Active comparator
    Placebo Arm + Standard of Care

    Subjects in this arm would receive, placebo (0.1 ml vehicle solution into each nostril).

    Other: Placebo

Interventions

  • Foralumab is a second generation fully human anti-CD3 antibody

  • OtherPlacebo

    Placebo will be the vehicle for the foralumab nasal solution without active drug (25 mM sodium acetate/125 mM sodium chloride/0.02% polysorbate 80, pH 5.5 buffer).

06

What researchers measure

Primary outcomes

  1. To evaluate the effect of intranasal foralumab on evolution of pulmonary infiltrates in hospitalized subjects with severe COVID-19 pneumonia

    It is determined based on change from baseline in semiquantitative chest CT severity score.A chest CT severity score was calculated by assessing the degree of lobe involvement for each of the five lung lobes separately as follows: 0% (no involvement), 1%-25% (minimal involvement), 26%-50% (mild involvement), 51%-75% (moderate involvement), and 76%-100% (severe involvement). Higher the score the worse the outcome.

    Time frame: Day 14 and Day 28

Secondary outcomes

  1. To evaluate the effect of intranasal foralumab on resolution of severe COVID-19 as assessed by chest CT severity score

    Proportion of randomized subjects with chest CT severity score \< 19.5

    Time frame: Day 14 and Day 28

  2. To evaluate the safety of intranasal foralumab when administered up to 14 days

    Adverse events categorized and graded via CTCAE

    Time frame: Day 28

  3. To assess the impact of intranasal foralumab on nasal symptoms when administered up to 14 days

    Change from baseline in subject-reported Intranasal Tolerability Rating Scale (ITRS). ITRS is rated on an 11-point scale, ranging from 0 (none) to 10 (worst I can imagine) and consists of 3 questions.

    Time frame: Day 14

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2022; primary completion for Oct 2022, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2021
First posted
Jul 30, 2021
StartEst.
Apr 30, 2022
Primary completionEst.
Oct 30, 2022
CompletionEst.
Dec 30, 2022
Last update
Oct 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04983446
Lead sponsor
Tiziana Life Sciences LTD
Responsible party
Sponsor
First posted
Jul 30, 2021
Start date
Apr 30, 2022 (estimated)
Primary completion
Oct 30, 2022 (estimated)
Completion
Dec 30, 2022 (estimated)
Last update
Oct 19, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Foralumab

Start the discussion